Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on October 26, 2020. The Company is a clinical-stage biopharmaceutical firm focused on developing therapies for type 1 diabetes and Alzheimer's disease. The report details updates on clinical development plans for its lead candidates, TTP399 and azeliragon, and provides an update on its liquidity position as of September 30, 2020.
Key Financial Metrics and Liquidity
The filing does not provide audited revenue, profit, or cash flow statements for the period. However, it discloses estimated liquidity sources as of September 30, 2020:
- Cash and Cash Equivalents: Approximately $1.8 million.
- Undrawn Letter of Credit: Approximately $3.0 million available under an agreement with MacAndrews and Forbes Group LLC.
- ATM Offering Availability: Approximately $2.8 million remaining under a $13.0 million Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co.
- ATM Proceeds (YTD): Sold 3,847,405 shares for gross proceeds of approximately $10.2 million during the nine months ended September 30, 2020.
Note: The Company states these liquidity figures are estimates subject to revision upon completion of quarterly closing procedures.
Material Changes and Clinical Updates
TTP399 (Type 1 Diabetes)
Following FDA responses on September 24, 2020, the Company updated its pivotal study plan:
- Plans to conduct a placebo-controlled six-month trial in approximately 400 subjects.
- A second pivotal trial will follow 9-12 months after the first.
- The FDA confirmed that a reduction in hypoglycemia events is an acceptable clinical endpoint.
- A mechanistic study to assess impact on ketone body formation is planned for initiation in Q1 2021.
Azeliragon (Alzheimer's Disease)
On September 30, 2020, the Company concluded enrollment for the Elevage Study:
- Enrollment: 43 patients with mild probable Alzheimer's disease and type 2 diabetes.
- Timeline: Top-line results are expected in December 2020, earlier than previously anticipated.
- Objective: To replicate cognitive improvement results observed in a post-hoc analysis of the Phase 3 STEADFAST trial.
Guidance, Risks, and Contingencies
The filing contains no formal financial guidance or revenue outlook. Key risks and contingencies include:
- Financial Estimates: Liquidity figures are preliminary estimates and may differ materially from final GAAP financial statements.
- Clinical Execution: Future funding and operations depend on the successful execution of the updated pivotal trials for TTP399 and the Elevage Study for azeliragon.
- Regulatory Dependence: Development plans are contingent on continued alignment with FDA recommendations.
Investor Verification Checklist
- Verify the final audited cash balance and liquidity position in the upcoming Form 10-Q for the quarter ended September 30, 2020.
- Monitor the initiation date of the TTP399 mechanistic study scheduled for Q1 2021.
- Track the release of top-line results for the azeliragon Elevage Study expected in December 2020.
- Review the remaining capacity and utilization rate of the $13.0 million ATM offering in future filings.